Gilead Sciences: First-Quarter Results Beat Estimates

Motley Fool04-30

Non-GAAP earnings and total revenue exceeded analysts' consensus expectations. A one-time charge related to its acquisition of CymaBay Therapeutics sapped its earnings. Management ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2431259208?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F774593%2Fresearch-scientists-drugs-pharma-biotech-1200x800-5b2df79.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-04-30 04:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2431259208","market":"fut","top_or_hot":-1,"title":"Gilead Sciences: First-Quarter Results Beat Estimates","media":"Motley Fool","content":"<div>\n<p>Non-GAAP earnings and total revenue exceeded analysts' consensus expectations.\n\n\n\n\n\n\n\nA one-time charge related to its acquisition of CymaBay Therapeutics sapped its earnings.\n\n\n\n\n\n\n\nManagement ...</p>\n\n<a href=\"https://www.fool.com/data-news/2024/04/29/gileads-first-quarter-results-beat-estimates/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences: First-Quarter Results Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences: First-Quarter Results Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-30 04:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/data-news/2024/04/29/gileads-first-quarter-results-beat-estimates/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Non-GAAP earnings and total revenue exceeded analysts' consensus expectations.\n\n\n\n\n\n\n\nA one-time charge related to its acquisition of CymaBay Therapeutics sapped its earnings.\n\n\n\n\n\n\n\nManagement ...</p>\n\n<a href=\"https://www.fool.com/data-news/2024/04/29/gileads-first-quarter-results-beat-estimates/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://www.fool.com/data-news/2024/04/29/gileads-first-quarter-results-beat-estimates/","article_id":"2431259208","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F774593%2Fresearch-scientists-drugs-pharma-biotech-1200x800-5b2df79.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431259208","pubTimestamp":1714424100,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The biopharmaceutical giant topped its earnings and revenue estimates thanks to strong sales of its HIV, liver disease, and oncology treatments.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"吉利德科学：第一季度业绩超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"Non-GAAP earnings and total revenue exceeded analysts' consensus expectations.\n\n\n\n\n\n\n\nA one-time charge related to its acquisition of CymaBay Therapeutics sapped its earnings.\n\n\n\n\n\n\n\nManagement revised its full-year EPS guidance downward due to issues related to the acquisition, but maintained its sales forecast.\n\nGilead Sciences (GILD 0.80%), a biopharmaceutical company known for its innovations in HIV and hepatitis C treatments, released its earnings report for the first quarter of 2024 on April 25. The company reported a non-GAAP diluted loss of $1.32 per share, outperforming analysts' expectations for a loss of $1.49 per share. Its Q1 revenue grew 5% year over year to $6.69 billion, compared to the analysts' average expectation of $6.36 billion.Despite management's decision to take a write-down on acquired in-process research and development assets from its purchase of CymaBay Therapeutics, which closed in March, Gilead's financial performance and sector-leading HIV product sales depict a robust quarter overall.MetricQ1 2024EstimatesQ1 2023% ChangeTotal revenue$6.69 billion$6.36 billion$6.35 billion5%Non-GAAP diluted EPS($1.32)($1.49)$1.37N/AHIV product sales$4.34 billionN/A$4.19 billion4%Oncology sales$789 millionN/A$670 million18%Liver disease sales$737 millionN/A$675 million9%Understanding Gilead SciencesGilead Sciences is a pioneer in the biopharmaceutical industry, focusing on life-saving treatments for HIV, hepatitis, oncology, and inflammatory and respiratory diseases. Its HIV treatments dominate that market, and it continues to research and develop new therapies to combat viral diseases. Its acquisition of CymaBay Therapeutics -- which brought the promising liver disease treatment candidate Seladelpar into its portfolio -- underscores its commitment to expanding its therapeutic footprint.The company's financial strength is largely attributable to its HIV product lineup, led by Biktarvy and Truvada, and its burgeoning oncology division, which is spearheaded by Trodelvy. This strategic diversity positions Gilead for sustainable growth amid evolving healthcare challenges.Quarterly highlightsGilead's key HIV, liver disease, and oncology segments showed notably strong Q1 performances, with new launches and global expansion fueling its sales. Sales of Biktarvy, its leading HIV treatment, rose 10%, highlighting Gilead's continued dominance in this niche. Its 18% year-over-year growth in oncology sales reflected the company's success in expanding its cancer treatment portfolio.It also took a significant impairment charge on in-process research and development from its CymaBay acquisition -- a purchase made to diversify and strengthen its long-term pipeline. Despite that write-down, the company's overall sales growth and operational adjustments exhibit a solid business trajectory.Looking aheadGilead's management adjusted its full-year EPS outlook downward, attributing those changes primarily to the financial impacts of its recent acquisition. Previously, it was forecasting non-GAAP (generally accepted accounting principles) diluted EPS in the $6.85 to $7.25 range. Now, it's guiding for a $3.45 to $3.85 range. It kept its product sales outlooks steady, however, signaling confidence in the continuing strength of its core business. Investors should keep a particular eye on how Gilead's integration of CymaBay progresses, and watch for developments from its pipeline.Given the strategic significance of Gilead's R&D investments and pipeline development, stakeholders should also pay attention to upcoming trial results and news regarding regulatory approvals. These factors, combined with market dynamics in the HIV and Oncology segments, will be crucial in determining Gilead's performance in the forthcoming quarters.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431259208"}